Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
March 18, 2011
Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
January 7, 2011 / ProteoMonitor - GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Kinaxo Receives European Patent for Chemical Proteomics Technology
April 15, 2011 / ProteoMonitor